Antimetabolic Agents
Antimetabolites are a cornerstone of modern dermatologic therapy, particularly for benign epidermal hyperproliferation and chronic inflammatory and autoimmune disorders. Because they mimic natural metabolites such as folic acid, purines and pyrimidines, these drugs interfere directly with nucleotide synthesis and block DNA and RNA replication during the S phase of the cell cycle. In dermatology, they markedly slow keratinocyte division and curb the explosive proliferation of autoreactive T and B lymphocytes.
At Haute-Derma, antimetabolite regimens are tailored to each patient. We screen drug-metabolizing enzyme activity and assess the risk of bone marrow and liver toxicity, aiming for the best clinical result with the widest possible safety margin.
Mechanism of Action and Pharmacodynamics
Disrupting Nucleotide Synthesis and the Cell Cycle
Antimetabolites are structurally similar to essential biomolecules, tricking cells into using them in biochemical reactions:
- Blocking purine and pyrimidine synthesis: The drugs compete with or inactivate key enzymes such as DHFR, IMPDH and thymidylate synthase. Starved of purines and pyrimidines, the cell cannot complete DNA replication in S phase.
- Selective inhibition of lymphocytes: Activated T and B lymphocytes rely entirely on de novo purine synthesis to proliferate, whereas other cells can fall back on the salvage pathway. This is why some antimetabolites, such as mycophenolate mofetil, are highly selective immunosuppressants.
Effects on Keratinocytes and Tissue Inflammation
- Controlling epidermal overgrowth: In psoriasis, the keratinocyte cycle shrinks from about 28 days to just 3–4 days. Antimetabolites help stretch it back toward its normal physiological length.
- Suppressing pro-inflammatory cytokines: They reduce production of inflammatory signals such as TNF-alpha, IL-2 and IFN-gamma, limiting neutrophil and monocyte infiltration into affected skin.
Main Classes of Antimetabolites in Dermatology
Folic Acid Antagonists
- Methotrexate (MTX): The archetypal agent, which inhibits DHFR. Used for severe plaque psoriasis, psoriatic arthritis, treatment-resistant atopic dermatitis and scleroderma.
Purine Antagonists
- Azathioprine (AZA): A prodrug of 6-MP that is incorporated into DNA/RNA and disrupts genetic replication. Used mainly for autoimmune blistering diseases (pemphigus, pemphigoid) and severe contact dermatitis.
- Mycophenolate mofetil (MMF) and mycophenolic acid (MPA): Selectively inhibit IMPDH type II and halt B- and T-cell proliferation. Preferred for pemphigus, cutaneous lupus and scleroderma.
Pyrimidine Antagonists
- Fluorouracil (topical 5-FU): A pyrimidine antagonist applied as a 5% or 0.5% cream that inhibits thymidylate synthase. Used topically for actinic keratosis and Bowen disease, and by injection in combination therapy for keloids.
Managing Toxicity and Clinical Safety
- Bone marrow suppression (myelosuppression): The most serious complication of purine and folate antagonists. Patients may develop neutropenia (below 1,500/µL), thrombocytopenia or pancytopenia.
- Screening drug-metabolizing enzymes (TPMT and MTHFR): Measuring TPMT activity before prescribing azathioprine helps prevent marrow toxicity from 6-TGN accumulation. Azathioprine is contraindicated in patients with homozygous TPMT deficiency.
- Liver and lung toxicity: Long-term oral methotrexate can cause progressive transaminase elevation, liver fibrosis or hypersensitivity pneumonitis. Folic acid 5 mg/week reduces side effects without blunting its effect on psoriasis.
- Reproductive effects and birth defects: All systemic antimetabolites can be teratogenic. Both men and women must use effective contraception throughout treatment and for 3–6 months after stopping.
Treatment and Monitoring at Haute-Derma
Pre-Treatment Evaluation
- Complete blood count (CBC) with platelet and reticulocyte counts.
- Liver function (AST, ALT, total bilirubin) and kidney function (eGFR, creatinine).
- Screening for hidden infections: hepatitis B, hepatitis C and latent tuberculosis (QuantiFERON-TB Gold).
- TPMT enzyme activity (if azathioprine is planned) and a mandatory pregnancy test for women of childbearing age.
Regimens and Dosing
- Methotrexate: A single dose once a week (starting at 7.5–10 mg/week), with folic acid 5 mg taken 24 hours after the methotrexate dose.
- Azathioprine: Start at 1 mg/kg/day and adjust according to TPMT activity.
- Mycophenolate mofetil: Start at 1 g/day in two divided doses, increasing to 2 g/day after 2 weeks.
Monitoring Schedule
- CBC and liver enzymes every 2 weeks for the first month, every 4 weeks for the next 2 months, then every 2–3 months.
- Treatment is paused if the white cell count falls below 3,000/µL, platelets fall below 100,000/µL, or AST/ALT rise above 3 times the upper limit of normal.
